Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1149186 | 0.86 | CA2 (0.38) | — | |
| SCHEMBL14770296 | 0.86 | CA2 (0.43) | — | |
| SCHEMBL3906374 | 0.77 | — | — | |
| SCHEMBL8189879 | 0.76 | CA2 (0.56) | TSHR | |
| SCHEMBL7136342 | 0.76 | CA2 (0.45) | — | |
| SCHEMBL9339421 | 0.74 | APP (0.46) | TSHR | |
| SCHEMBL8080559 | 0.74 | — | — | |
| SCHEMBL1118598 | 0.73 | — | — | |
| SCHEMBL3618484 | 0.73 | — | — | |
| SCHEMBL11608955 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3674298-B9 | SUBSTITUTED INDAZOLES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND THEIR USE FOR THE PREPARATION OF MEDICAMENTS | Bayer Pharma AG (DE) | 2024-06-19 | — | — | EP | disclosed |
| EP-3674298-B1 | SUBSTITUTED INDAZOLES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL FORMULATIONS CONTAINING THEM, AND THEIR USE FOR THE PREPARATION OF MEDICAMENTS | Bayer Pharma AG (DE) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023215376-A1 | METHODS OF TREATING NEUROPATHIES | ATHIRA PHARMA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215377-A1 | METHODS OF TREATING NEUROINFLAMMATORY CONDITIONS | ATHIRA PHARMA, INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| EP-4260909-A2 | SUBSTITUTED INDAZOLES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND THEIR USE IN THE PREPARATION OF DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023114456-A1 | USES OF BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES | ATHIRA PHARMA, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| CN-109152771-B | Use of 2-substituted indazoles for the treatment and prevention of autoimmune diseases | 拜耳医药股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| US-20220135544-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2022-05-05 | — | — | US | disclosed |
| CN-110305109-B | Novel substituted indazoles, method for the production thereof, pharmaceutical preparations containing same, and use thereof for producing medicaments | 拜耳医药股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| CN-113748104-A | Isoquinolinone compound for inhibiting SSAO/VAP-1 and application thereof | 广东东阳光药业有限公司 | 2021-12-03 | — | — | CN | disclosed |
| WO-2015193339-A1 | 3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015144799-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-PYRAZOLO[1,5-a]PYRAZINE DERIVATIVES AND 5,6,7,8-TETRAHYDRO-4H-PYRAZOLO[1,5-a][1,4]DIAZEPINE DERIVATIVES AS ROS1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-01 | — | — | WO | disclosed |
| US-20150105368-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-04-16 | — | — | US | disclosed |
| US-8895601-B2 | Pyrazolyl quinoxaline kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2014-11-25 | — | — | US | disclosed |
| US-20140288053-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| EP-2776435-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | Astex Therapeutics Limited (GB) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013061080-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
| US-20130072457-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-21 | — | — | US | disclosed |
| EP-2563775-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | Astex Therapeutics Limited (GB) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011135376-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072457-A1 | PYRAZOLYL QUINAZOLINE KINASE INHIBITORS | MAP3K5, MAP3K1, MAP4K2 | APEX1 1940/4885TSHR 3825/4885 |
| US-20150105368-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | PDXK, DCK, PDPK1 | APEX1 1597/4885TSHR 3913/4885 |
| US-20140288053-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | FGFR1, FGFR2, FGFR4 | APEX1 3621/4885TSHR 3035/4885 |
| US-20220135544-A1 | PYRAZOLYL QUINOXALINE KINASE INHIBITORS | PDXK, DCK, PDPK1 | APEX1 1597/4885TSHR 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.